Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma

Trial Profile

Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Sorafenib (Primary) ; Ritonavir
  • Indications Kaposi's sarcoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 01 May 2017 According to results published in the Oncologist Journal, patients were accrued between January 2006 and February 2012.
    • 15 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top